MUSCULAR DYSTROPHY TREATMENT MARKET ANALYSIS

Muscular Dystrophy Treatment MarketSize and Trends

Rising prevalence of muscular dystrophies with unspecific current medications is expected to fuel the muscular dystrophies treatment market

According to the research conducted by the Karger Journal on 2014, the global prevalence for muscular dystrophies accounted between 19.8 and 25.1 per 100,000 person every year with myotonic dystrophy (0.5-18.1 per 100,000), duchenne muscular dystrophy (1.7-4.2) and facioscapulohumeral muscular dystrophy (3.2-4.6 per 100,000) to be the most common types of disorders. The initial research phase of the therapies and ongoing clinical trials for the development of innovative products drives the global muscular dystrophy treatment market. Also, specific guidance for drug development for muscular dystrophy drugs published by the U.S. FDA in 2015 is expected to accelerate the new drug development for the treatment of a disorder. The emergence of disease-modifying therapies as a replacement for the unmet medical needs of patients who are not amenable to mutation-specific drugs is likely expected to fuel the revenue of the global muscular dystrophy treatment market in the forecast period. However, the fast prognosis of a disorder and low treatment seeking rate due to delayed diagnosis are the major limiting factors for the growth of global muscular dystrophy treatment market.

Market- Trends

• Muscular dystrophy is a genetic disease and the chance of an individual developing a disease increases with a history of muscular dystrophy in the family.
• Rising prevalence of muscular dystrophies with unspecific current medications is expected to fuel the muscular dystrophies treatment market.
• Specific guidance for drug development for muscular dystrophy drugs published by the U.S. FDA in 2015 is expected to accelerate the new drug development for the treatment of a disorder.
• The emergence of disease-modifying therapies as a replacement for the unmet medical needs of patients who are not amenable to mutation-specific drugs is likely to fuel the revenue of the global muscular dystrophy treatment market in the forecast period.